New CEO for Medical Technology Association of Australia
30 September, 2013The Medical Technology Association of Australia Limited has appointed Susanne Tegen as its new chief executive officer.
Bioniche posts last results before animal health sale
30 September, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has reported its FY13 results and completed a Canadian equity offering and private placement to raise C$9.8m.
First Parkinson's patient implanted with LCT's NTCELL
27 September, 2013 by Dylan Bushell-EmblingThe first Parkinson's patient has been implanted with Living Cell Technologies' (ASX:LCT) NTCELL regenerative treatment during a phase I trial.
pSivida Q4 loss rises on phase III trial spending
26 September, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) attributed costs associated with initiating its phase III trial of Medidur in posterior uveitis for a 69% higher Q4 loss.
AusBiotech joins forces with Cook Medical and Deloitte on tax
26 September, 2013Biotechnology industry experts are joining forces to support a 'patent box' tax incentive, like that recently introduced on the UK, to keep home-grown IP in Australia and keep the local medical manufacturing industry globally competitive.
Allied's CardioCel stands the test of time
26 September, 2013 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) said paediatric heart defect patients treated using its CardioCel tissue patch have shown no sign of calcification at the site of repair after up to five years of monitoring.
iSonea launches AirSonea in Australia
25 September, 2013 by Dylan Bushell-EmblingiSonea's flagship AirSonea smartphone-compatible asthma wheeze monitoring device was launched in Australia today by gold medallist Cathy Freeman.
Vic govt offering grants for high-tech projects
25 September, 2013 by Dylan Bushell-EmblingThe Victorian Government has launched a new round of its Technology Implementation voucher program, giving the state's life science sector a chance to again take advantage of the opportunity.
Mesoblast spine trial to be presented at NASS meet
24 September, 2013 by Dylan Bushell-EmblingThe lead investigator for a trial of Mesoblast's (ASX:MSB) MPCs in spinal fusion procedures will present details from the study at next month's North American Spine Society meeting.
Innate Immunotherapeutics plans move across Tasman
24 September, 2013 by Susan WilliamsonNew Zealand biopharmaceutical company Innate Immunotherapeutics will migrate across the Tasman this month in a bid to get its Phase IIb trial financed and underway in Australia.
Nominate an industry leader for recognition they deserve
24 September, 2013The 2013 Janssen Industry Excellence Awards close this Friday 27 September. This is the last chance in 2013 to nominate an individual or organisation that has made a significant contribution to the biotechnology industry.
Phosphagenics commences TPM/oxymorphone trial
20 September, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has started dosing volunteers in a phase I trial of pain patch candidate TPM/oxymorphone and aims to enter phase II in 1H14.
Pharmaxis to reduce board size to four
20 September, 2013 by Dylan Bushell-EmblingTwo Pharmaxis (ASX:PXS) independent directors have retired and the newly-restructured company is using the opportunity to shave down its board size.
Freehills adds new partner
20 September, 2013Freehills Patent Attorneys has appointed another a partner in their pharmaceutical and biotechnology practice.
BioDiem's BDM-I presented at antimicrobial meet
19 September, 2013 by Dylan Bushell-EmblingA poster presentation detailing the activity of BioDiem's (ASX:BDM-I) animicrobial BDM-I in nearly 70 fungal infections has been presented at an interscience conference.
